Pila Pharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 3

Employees

  • Stock Symbol
  • PILA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.44
  • (As of Friday Closing)

Pila Pharma General Information

Description

Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Norra Vallgatan 72
  • Malmo
  • Sweden
+46 073-903
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Norra Vallgatan 72
  • Malmo
  • Sweden
+46 073-903

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pila Pharma Stock Performance

As of 08-Nov-2024, Pila Pharma’s stock price is $0.44. Its current market cap is $12M with 27.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.44 $0.43 $0.09 - $0.88 $12M 27.1M 76.9K -$0.02

Pila Pharma Financials Summary

As of 30-Jun-2024, Pila Pharma has a trailing 12-month revenue of $97.1K.

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 9,024 3,842 4,984 8,371
Revenue 97 138 185 84
EBITDA (545) (829) (2,638) (1,998)
Net Income (650) (934) (2,639) (2,004)
Total Assets 422 846 1,044 3,515
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pila Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pila Pharma‘s full profile, request access.

Request a free trial

Pila Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Pila Pharma‘s full profile, request access.

Request a free trial

Pila Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel ty
Drug Discovery
Malmo, Sweden
3 As of 2024

North Chicago, IL
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pila Pharma Competitors (13)

One of Pila Pharma’s 13 competitors is AbbVie, a Corporation company based in North Chicago, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AbbVie Corporation North Chicago, IL
Roche Corporation Basel, Switzerland
TRPV Pharmaceuticals Corporation Stuart, FL
Eli Lilly and Company Corporation Indianapolis, IN
Amgen Formerly PE-Backed Thousand Oaks, CA
You’re viewing 5 of 13 competitors. Get the full list »

Pila Pharma Patents

Pila Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2487238-A1 Hydroxy tetrahydro-naphthalenylurea derivatives Active 08-May-2002
US-20060258742-A1 Such as n-[4-chloro-3-(trifluoromethyl)phenyl]-n'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, copd Active 08-May-2002
US-7612113-B2 Such as n-[4-chloro-3-(trifluoromethyl)phenyl]-n'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, copd Active 08-May-2002
CA-2487238-C Hydroxy tetrahydro-naphthalenylurea derivatives Inactive 08-May-2002
AU-2003229734-A1 Hydroxy tetrahydro-naphthalenylurea derivatives Active 08-May-2002 C07C275/42
To view Pila Pharma’s complete patent history, request access »

Pila Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pila Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pila Pharma‘s full profile, request access.

Request a free trial

Pila Pharma Investments (2)

Pila Pharma’s most recent deal was a Later Stage VC with Dilafor for . The deal was made on 27-Sep-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dilafor 27-Sep-2016 Later Stage VC Drug Discovery
Ario Pharma (TRPV1 Antagonist Molecule) 30-Mar-2016 Corporate Asset Purchase Buildings and Property
To view Pila Pharma’s complete investments history, request access »

Pila Pharma FAQs

  • When was Pila Pharma founded?

    Pila Pharma was founded in 2014.

  • Where is Pila Pharma headquartered?

    Pila Pharma is headquartered in Malmo, Sweden.

  • What is the size of Pila Pharma?

    Pila Pharma has 3 total employees.

  • What industry is Pila Pharma in?

    Pila Pharma’s primary industry is Drug Discovery.

  • Is Pila Pharma a private or public company?

    Pila Pharma is a Public company.

  • What is Pila Pharma’s stock symbol?

    The ticker symbol for Pila Pharma is PILA.

  • What is the current stock price of Pila Pharma?

    As of 08-Nov-2024 the stock price of Pila Pharma is $0.44.

  • What is the current market cap of Pila Pharma?

    The current market capitalization of Pila Pharma is $12M.

  • What is Pila Pharma’s current revenue?

    The trailing twelve month revenue for Pila Pharma is $97.1K.

  • Who are Pila Pharma’s competitors?

    AbbVie, Roche, TRPV Pharmaceuticals, Eli Lilly and Company, and Amgen are some of the 13 competitors of Pila Pharma.

  • What is Pila Pharma’s annual earnings per share (EPS)?

    Pila Pharma’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »